Abstract Book

S58

ESTRO 37

Abstract text Topics that will be covered in this session include: Review of the 5-year results from RTOG 0617 Review of multiple secondary analyses: -Quality of life -Value of IMRT -Impact of institutional enrollment volume -Heart DVH data Current concepts escalating radiation dose for NSCLC in North America SP-0110 Combining systemic therapy with hypofractionation in locally dvanced NSCLC: Best of both worlds, or double-trouble? G. Hanna Queen´s University of Belfast, Belfast, the United Kingdom SP-0111 Model-based approach to select the optimal technology for LA-NSCLC J.J. Sonke 1 1 Netherlands Cancer Institute, Radiotherapy department, Amsterdam, The Netherlands Abstract text Locally advanced lung cancer is a challenging disease site to treat with radiation. Tumors are located within and nearby sensitive normal structures, both day-to-day baseline shifts and respiration induce motion of the primary tumor and lymph nodes relative to the bony anatomy and each other, anatomical changes occur frequently and tumor regression is common. Various technologies are being developed to meet those challenges such as kilo-voltage intra-fraction monitoring (KIM), PET guided RT, MR guided RT and proton therapy. Randomized clinical trials, however, are lacking to select the best technology for given patient. In fact, as technologies are not fixed but continuously evolving improvements, it is unlikely that such clinical trials will ever provide a definitive answer. Model-based selection is an alternative approach to guide the use of the optimal technology. In the model based approach, for each patient a treatment plan is made for one or more technologies as well as the standard of care. Subsequently, state of the art normal-tissue complication probability (NTPC) models are used to estimate and compare the likelihood of treatment related toxicities for each technology of interest. This allows the selection of the optimal technology, in terms of cost and effect. The potential and caveats of this model based approach for LA-NSCLC patient specific technology selection will be discussed. SP-0112 Dose to cardiac substructures predicts survival in non-small cell lung cancer chemo- radiotherapy M. Thor 1 , A. Hotca 2 , A. Jackson 1 , E. Yorke 1 , A. Rimner 2 , J. Deasy 1 1 Memorial Sloan Kettering Cancer Center, Medical Physics, New York City, USA 2 Memorial Sloan Kettering Cancer Center, Radiation Oncology, New York City, USA Purpose or Objective Recent findings suggest that survival after non-small cell lung cancer (NSCLC) chemo-radiotherapy (CRT) drops as dose to the heart increases. We aimed to investigate this further incorporating dose to 13 cardiac substructures, the whole heart, and the tumor-subtracted lung together with disease- and patient characteristics in prediction models for overall survival (OS), and non-cancer related survival (NCS). Abstrat not received

to surgery had markedly increased survival than patients who did not undergo surgery (median, 103.8 vs. 13.1 months; p < 0.001). PIVKA-II responses were significantly higher in the ≥ 72 Gy group (85.2% vs. 67.8%, p=0.002). There were no significant differences in the rate of gastrointestinal bleeding. The rates of classic and nonclassic radiation-induced liver disease were not increased in the ≥ 72 Gy group. Conclusion High dose radiation increased local control and conversion rate to surgery in liver-directed CCRT, which contributed to improved survival. CCRT with high-dose radiation can be an effective treatment option in patients with locally advanced BCLC-C HCC.

Presidential Symposium: Presidential symposium

SP-0107 Re/Mind Value Abstract not received

Award lecture: Emmanuel Van der Schueren Award

SP-0108 The ESTRO School - Radiation oncology education of the highest standard for all C. Verfaillie ESTRO, Education and Science, Brussels, Belgium Abstract text One of the first priorities of the ESTRO founders was to assist in providing and harmonizing education in radiotherapy: dedicated training was almost non-existent in many parts of Europe and standards of practice in radiation oncology needed to be set. Prof. van der Schueren initiated the first ESTRO course in 1985; in the next two decades, the ESTRO educational program was growing exponentially and as of the creation of the ESTRO School in 2005, the number of activities and resources started snowballing. The ESTRO School became one of the main flagships of the Society, about 500 courses were organized in Europe and beyond, more than 50.000 learners participated to the live and online activities of the School and numerous ESTRO members shared their time and expertise as teachers and tutors to make this possible. The ESTRO School has developed a wide spectrum of activities and approaches to support most of the scientific and professional needs of its community. A lot of effort was put in improving the teaching processes. Still, the ESTRO School can do much more and better in the future: gearing up to the challenges ahead and preparing the next generation of radiation oncology professionals to provide excellent care to cancer patients is a life-long responsibility of the ESTRO School. This lecture will discuss opportunities for the School to optimize the teaching approaches and learning outcome, integrate new methodologies and cost- effective technologies for enhanced access to learning and educational resources and scale up radiation oncology education & training worldwide.

Symposium: Lung and dose escalation

SP-0109 Lessons Learned from RTOG 0617 J. Bradley 1 1 Washington University School of Medicine, Department of Radiation Oncology, St. Louis, USA